Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Ario Pharma is focused on the development of drugs for the treatment of respiratory indications.
Dezima Pharma develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia.
Amakem is a kinase platform company developing therapeutics for the treatment of serious eye conditions.
gIcare Pharma is a Canada-based company that develops novel gastrointestinal drugs for unmet medical needs.
Forbion Capital Partners has invested in 124 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Pharmaceutical, Therapeutics, Biopharma, Medical. The firm invests across 6 different industry categories.
Among tracked funding rounds, Dezima Pharma received $18.6M in a Series Unknown round. Forbion Capital Partners's total known invested capital is $12.0B.
Forbion Capital Partners's average investment size is $96.6M across its portfolio of 124 companies.